Ligand ID: PAR


Drugbank ID:
DB01421
(Paromomycin)


Indication:
For the treatment of acute and chronic intestinal amebiasis (it is not effective in extraintestinal amebiasis). Also for the management of hepatic coma as adjunctive therapy.

Get human targets for PAR in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'PAR'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		1q2w 3C-LIKE PROTEASE
(SARSr-CoV)		5 / 12
GLY B 124
LEU A 115
GLU A  14
VAL A  13
ASP A 155
1.79A20.26
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4KHP_A_PARA1606_1
(16S RIBOSOMAL RNA
30S RIBOSOMAL
PROTEIN S9
30S RIBOSOMAL
PROTEIN S10)		1ssk NUCLEOCAPSID PROTEIN
(SARSr-CoV)		3 / 3
TYR A  87
ARG A 127
SER A  29
1.64A22.56
23.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		1x7q BETA-2-MICROGLOBULIN
HLA, A-11
(Homo
sapiens)		5 / 10
SER B  55
PHE B  62
SER B  52
GLU A  46
TYR A   9
1.77A11.45
GOL  A5003 ( 4.6A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		1x7q BETA-2-MICROGLOBULIN
HLA, A-11
(Homo
sapiens)		5 / 9
PHE B  30
SER B  55
THR A  10
SER B  33
ASP A  74
1.78A11.45
None
GOL  A5003 ( 4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_2
(AAC(6')-IB)		1x7q BETA-2-MICROGLOBULIN
HLA, A-11
(Homo
sapiens)		3 / 3
TRP A 133
GLN A 141
TRP B  60
1.42A23.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		1x7q HLA, A-11
(Homo
sapiens)		5 / 10
ASP A 137
TYR A 123
THR A 134
THR A 143
GLU A 148
1.73A22.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
PHE B1159
SER B1010
GLU B1290
ASP B1295
1.27A23.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		2ahm REPLICASE
POLYPROTEIN 1AB,
LIGHT CHAIN
(SARSr-CoV)		3 / 3
SER C   6
LYS C   7
SER C   9
0.78A19.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2ajf ACE2
(Homo
sapiens)		5 / 11
SER B 511
GLU B 197
ASP B 198
ASP B 201
GLY B 205
1.79A21.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		5 / 10
PHE C 316
SER C 311
THR D 297
ASP D 298
TYR D 269
1.68A12.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4KHP_A_PARA1606_1
(16S RIBOSOMAL RNA
30S RIBOSOMAL
PROTEIN S9
30S RIBOSOMAL
PROTEIN S10)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		3 / 3
TYR A 269
ARG A 263
SER A 256
1.74A19.73
18.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		4 / 8
PHE E 316
SER E 311
THR F 297
TYR F 269
1.39A12.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		5 / 9
PHE C 316
SER C 311
THR D 297
ASP D 298
TYR D 269
1.68A12.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2d2d 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 10
PHE A 291
SER B 139
PHE A   3
GLU B  14
TYR B 118
1.77A23.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2d2d 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.19A23.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2d2d 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
PHE A 291
SER B 139
PHE A   3
GLU B  14
TYR B 118
1.68A23.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_C_PARC500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2dd8 IGG LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 10
SER S 362
ASP L  92
ASP L  95
TYR S 491
GLY S 490
1.73A17.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2dd8 IGG LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
SER S 362
ASP L  92
ASP L  95
TYR S 491
GLY S 490
1.68A17.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2dd8 IGG LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 11
SER S 362
ASP L  92
ASP L  95
TYR S 491
GLY S 490
1.70A17.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2dd8 IGG LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 10
PHE S 360
SER S 362
ASP L  50
ASP L  51
GLY L  29
1.67A17.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2dd8 IGG LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		4 / 8
SER L  94
ASP S 392
ASP S 393
TYR S 410
1.36A17.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2fe8 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
PHE B  57
LEU B 151
GLU B  78
ASP B  77
GLY B  82
1.71A21.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		2fe8 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
GLY A  29
TYR A  36
LEU A  81
VAL A  12
ASP B  63
1.79A22.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		2fe8 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 10
THR B 171
THR A 159
GLY A 161
ASP A 109
GLU B 204
1.65A24.02
None
BR  A 319 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LF8_A_PARA1817_1
(16S RRNA
RIBOSOMAL PROTEIN S9
RIBOSOMAL PROTEIN
S10)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		3 / 3
TYR A 475
ARG B 186
SER B 195
1.50A21.57
20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LF7_A_PARA1817_1
(16S RRNA
RIBOSOMAL PROTEIN S9
RIBOSOMAL PROTEIN
S10)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		3 / 3
TYR A 475
ARG B 186
SER B 195
1.50A21.57
20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4KHP_A_PARA1606_1
(16S RIBOSOMAL RNA
30S RIBOSOMAL
PROTEIN S9
30S RIBOSOMAL
PROTEIN S10)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		3 / 3
TYR C 484
ARG D 223
SER D 101
1.76A21.54
17.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2ghw ANTI-SCFV ANTIBODY,
80R
(Homo
sapiens)		4 / 8
PHE B 230
GLU B  89
ASP B  90
TYR B  60
1.28A18.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		2ghw ANTI-SCFV ANTIBODY,
80R
(Homo
sapiens)		5 / 12
GLY D  42
TYR D 219
GLU D  46
VAL D  37
TYR D  94
1.63A22.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2gt8 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
TYR A 126
1.59A23.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)		4 / 8
SER A 161
GLU A 201
ASP A 202
ASP A 199
1.36A21.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		2jw8 NUCLEOCAPSID PROTEIN
(SARSr-CoV)		3 / 3
SER B 311
LYS A 262
SER B 313
1.26A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		2k87 NSP3 OF REPLICASE
POLYPROTEIN 1A
(SARSr)		5 / 12
GLY A  41
LEU A  50
GLU A  49
ASP A  21
ASP A 115
1.30A20.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		2kys NSP7
(SARSr-CoV)		5 / 12
LEU A  61
VAL A  60
GLN A  33
SER A  56
ASP A  40
1.62A20.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2q6g REPLICASE
POLYPROTEIN 1AB
(SARS-COV
BJ01)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.43A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2qcy 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
PHE A 150
SER A 113
GLU A 290
ASP A 295
1.29A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2vj1 MAIN PROTEINASE
(SARSr-CoV)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.37A23.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		2w2g NSP3
(SARSr-CoV)		5 / 10
TYR B 483
ASP B 481
THR B 450
GLY B 452
GLU B 432
1.66A23.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
PHE A  70
LEU A  85
THR A  82
TYR A  47
ASP A 106
1.61A19.95
None
None
None
SAH  A1293 (-4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2xyr PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
PHE A  70
LEU A  85
THR A  82
TYR A  47
ASP A 106
1.61A19.95
None
None
None
SFG  A1298 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		2z9k 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.32A23.40
None
None
None
DMS  A 813 ( 4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LF8_A_PARA1817_1
(16S RRNA
RIBOSOMAL PROTEIN S9
RIBOSOMAL PROTEIN
S10)		3bgf F26G19 FAB
(Mus
musculus)		3 / 3
TYR L  91
ARG L  46
SER L  34
1.53A18.78
17.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4KHP_A_PARA1606_1
(16S RIBOSOMAL RNA
30S RIBOSOMAL
PROTEIN S9
30S RIBOSOMAL
PROTEIN S10)		3bgf F26G19 FAB
(Mus
musculus)		3 / 3
TYR L  91
ARG L  46
SER L  34
1.36A21.79
16.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LF7_A_PARA1817_1
(16S RRNA
RIBOSOMAL PROTEIN S9
RIBOSOMAL PROTEIN
S10)		3bgf F26G19 FAB
(Mus
musculus)		3 / 3
TYR L  91
ARG L  46
SER L  34
1.53A18.78
17.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3bgf F26G19 FAB
(Mus
musculus)		4 / 8
SER B   7
GLU C  38
ASP C  41
TYR B  90
1.20A17.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		3 / 3
SER A 109
LYS A 112
SER A 113
1.70A14.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 8
THR B 294
ASP B 368
ASP B 367
TYR B 279
1.15A20.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3ea7 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.37A23.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		3eaj 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 10
ASP A 245
ASN B 133
THR B 135
GLY B 109
GLU B 290
1.58A25.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3f9e 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
PHE A 150
SER A  10
GLU A 290
ASP A 295
1.23A23.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3f9g 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.38A23.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3f9h 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.31A23.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3i6g BETA-2-MICROGLOBULIN
HLA, A-2
(Homo
sapiens)		4 / 8
SER D  11
THR D  94
SER E  33
TYR D 116
1.36A20.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_C_PARC500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3i6g BETA-2-MICROGLOBULIN
HLA, A-2
(Homo
sapiens)		5 / 10
SER D  11
PHE D  22
THR D  94
SER E  33
TYR D 116
1.47A20.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3i6g HLA, A-2
(Homo
sapiens)		5 / 11
PHE A  22
TYR A  99
GLU A  55
GLU A  58
GLY A  62
1.72A20.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3i6g BETA-2-MICROGLOBULIN
HLA, A-2
(Homo
sapiens)		5 / 12
SER D  11
PHE D  22
THR D  94
SER E  33
TYR D 116
1.52A20.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		3i6k HLA, A-2
(Homo
sapiens)		5 / 10
TYR A 209
ASP A  29
THR A 182
THR A 178
GLY A 175
1.70A23.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		3i6l HLA, A-24
(Homo
sapiens)		5 / 10
ASP D 137
TYR D 123
THR D 134
THR D 143
GLU D 148
1.72A22.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3i6l BETA-2-MICROGLOBULIN
HLA, A-24
(Homo
sapiens)		5 / 12
SER D  11
PHE D  22
THR D  94
SER E  33
TYR D 116
1.65A20.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3i6l BETA-2-MICROGLOBULIN
HLA, A-24
(Homo
sapiens)		4 / 8
PHE D  22
SER D  11
ASP D 119
TYR E  63
1.41A20.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3i6l BETA-2-MICROGLOBULIN
HLA, A-24
(Homo
sapiens)		5 / 9
PHE E  30
SER E  55
THR D  10
SER E  33
ASP D  74
1.76A11.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3m3s 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.32A23.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3m3t 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
PHE A 150
SER A 113
GLU A 290
ASP A 295
1.38A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3m3v 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.34A23.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
PHE A  70
LEU A  85
THR A  82
TYR A  47
ASP A 106
1.58A23.17
None
None
None
SAM  A 302 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3sci ACE2
(Homo
sapiens)		4 / 8
THR B 294
ASP B 368
ASP B 367
TYR B 279
1.22A21.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3scj ACE2
(Homo
sapiens)		5 / 11
SER A 511
GLU A 197
ASP A 198
ASP A 201
GLY A 205
1.59A21.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3scj ACE2
(Homo
sapiens)		5 / 10
SER A 511
GLU A 197
ASP A 198
ASP A 201
GLY A 205
1.57A21.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_C_PARC500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3scj ACE2
(Homo
sapiens)		5 / 10
SER A 511
GLU A 197
ASP A 198
ASP A 201
GLY A 205
1.68A21.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		3scj ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 10
TYR F 436
ASP B  38
THR F 433
THR F 487
ASP B 355
1.79A17.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3scj ACE2
(Homo
sapiens)		5 / 12
SER B 511
GLU B 197
ASP B 198
ASP B 201
GLY B 205
1.69A21.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
GLU A 197
ASP A 198
ASP A 201
TYR A 217
GLY A 220
1.59A20.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
GLU A 197
ASP A 198
ASP A 201
TYR A 217
GLY A 220
1.65A20.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 11
PHE B 314
SER B 547
SER B 411
GLU B 430
GLU A 536
1.72A20.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 8
THR B 294
ASP B 368
ASP B 367
TYR B 279
1.22A20.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3to2 BETA-2-MICROGLOBULIN
MHC CLASS I ANTIGEN
(Homo
sapiens)		5 / 10
SER A  11
PHE A  22
THR A  94
SER B  33
TYR A 116
1.54A20.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_2
(AAC(6')-IB)		3to2 BETA-2-MICROGLOBULIN
MHC CLASS I ANTIGEN
(Homo
sapiens)		3 / 3
TRP A 133
GLN A 141
TRP B  60
1.47A21.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 8
PHE D 367
THR D 372
SER D 369
ASP D 375
1.39A20.04
SAH  D 605 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5c8t GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 8
PHE D 367
THR D 372
SER D 369
ASP D 375
1.29A20.18
SAM  D 605 (-3.4A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
PHE B 431
LEU B 406
SER B 418
GLU B 302
GLY B 505
1.63A20.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4KHP_A_PARA1606_1
(16S RIBOSOMAL RNA
30S RIBOSOMAL
PROTEIN S9
30S RIBOSOMAL
PROTEIN S10)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		3 / 3
TYR B 446
ARG B 476
SER B 448
1.74A13.12
12.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		5f22 NSP7
(SARSr)		3 / 3
SER A  30
LYS A  32
SER A  31
1.44A19.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		5 / 10
SER B  56
PHE B   8
ASP B  99
TYR B 197
GLY B 123
1.72A21.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_C_PARC500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		5 / 10
SER B  56
PHE B   8
ASP B  99
TYR B 197
GLY B 123
1.74A21.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5r84 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.32A21.83
None
None
None
DMS  A1003 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.40A15.33
None
None
None
DMS  A 402 ( 4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER A 561
PHE A 551
SER A 542
TYR B 266
GLY B 270
1.72A15.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5x4r S PROTEIN
(MERS-CoV)		5 / 12
PHE A 228
PHE A 204
THR A 168
TYR A 292
GLY A 150
1.70A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5x4r S PROTEIN
(MERS-CoV)		5 / 10
PHE A 228
PHE A 204
THR A 168
TYR A 292
GLY A 150
1.60A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5x4r S PROTEIN
(MERS-CoV)		4 / 8
PHE A 101
SER A 133
SER A  88
ASP A 306
1.31A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 10
PHE A1085
SER A1093
PHE A1092
ASP A1100
GLY A1075
1.70A15.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
PHE B 741
SER A 950
LEU A 948
SER A 985
TYR A 723
1.51A15.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		5x59 S PROTEIN
(MERS-CoV)		5 / 12
GLY B1154
LEU B1200
GLU C 992
GLN C 974
SER C 991
1.58A9.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
TYR B 622
LEU B 597
GLU B 285
VAL B 581
GLN B 599
1.65A10.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5x5c S PROTEIN
(MERS-CoV)		5 / 9
PHE B 977
THR B 986
SER B 991
ASP B1182
GLY B 984
1.79A15.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5x5c S PROTEIN
(MERS-CoV)		4 / 8
SER B 607
SER B 643
ASP B 580
TYR B 438
1.07A15.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5x5f S PROTEIN
(MERS-CoV)		5 / 12
PHE C 467
SER C 504
LEU C 554
SER C 524
TYR C 540
1.62A15.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5x5f S PROTEIN
(MERS-CoV)		5 / 10
PHE C 228
PHE C 204
THR C 168
TYR C 292
GLY C 150
1.60A15.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
PHE C1091
THR C 894
SER C1093
GLU C1074
GLY C 892
1.79A15.45
PHE  C1091 ( 1.3A)
THR  C 894 ( 0.8A)
SER  C1093 ( 0.0A)
GLU  C1074 ( 0.6A)
GLY  C 892 ( 0.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
SER B 353
THR B 372
GLU A 970
ASP A 967
1.42A15.45
SER  B 353 ( 0.0A)
THR  B 372 ( 0.8A)
GLU  A 970 ( 0.5A)
ASP  A 967 ( 0.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5NDV_1_PAR13413_1
(25S RIBOSOMAL RNA
5S RIBOSOMAL RNA)		5yvd NSP15
(MERS-CoV)		3 / 3
LYS A  30
GLU A  44
LYS A  46
1.27A10.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		5zvm SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
SER A 949
LYS A 946
SER A 950
1.55A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
SER B 686
LYS A 772
SER B 685
1.70A11.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DR2_A_PARA1609_1
(16S RRNA
30S RIBOSOMAL
PROTEIN S9
30S RIBOSOMAL
PROTEIN S10)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
TYR C  88
ARG C  38
SER C  35
1.54A7.79
6.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
GLY B 536
LEU A 959
VAL A 958
ASP B 554
ASP B 572
1.43A10.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_C_PARC500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER A 574
PHE C 837
THR A 535
ASP A 312
GLY A 534
1.66A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_2
(AAC(6')-IB)		6acg ACE2
(Homo
sapiens)		3 / 3
TRP D  69
GLN D  42
TRP D 349
1.77A15.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LF8_A_PARA1817_1
(16S RRNA
RIBOSOMAL PROTEIN S9
RIBOSOMAL PROTEIN
S10)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
TYR A  63
ARG A 620
SER A  64
1.68A7.79
6.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LF7_A_PARA1817_1
(16S RRNA
RIBOSOMAL PROTEIN S9
RIBOSOMAL PROTEIN
S10)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
TYR A  63
ARG A 620
SER A  64
1.68A7.79
6.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
PHE A 379
TYR A 356
ASP C 967
TYR A 367
GLY A 368
1.77A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
ASP A  44
TYR A  53
THR A 271
GLY B 552
ASP B 560
1.74A13.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6ack ACE2
(Homo
sapiens)		5 / 12
TYR D  83
LEU D  97
GLU D  22
VAL D  93
ASP D  30
1.57A15.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
PHE B 741
SER C 985
SER C 950
ASP A 557
1.34A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
PHE A 741
SER B 950
LEU B 948
SER B 985
TYR B 723
1.46A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ack ACE2
(Homo
sapiens)		5 / 9
SER D 411
GLU D 375
ARG D 518
TYR D 381
GLY D 405
1.70A21.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 9
PHE C 545
SER C 561
ARG C 544
ASP A  50
GLY A 270
1.76A15.41
None
None
NAG  A1302 (-3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
PHE C 741
SER B 950
LEU B 948
SER B 985
TYR B 723
1.63A15.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
PHE C 784
PHE C 779
THR C 863
TYR C 771
GLY C 862
1.60A15.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LF7_A_PARA1817_1
(16S RRNA
RIBOSOMAL PROTEIN S9
RIBOSOMAL PROTEIN
S10)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		3 / 3
TYR C  88
ARG C  38
SER C  35
1.67A7.20
6.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LF8_A_PARA1817_1
(16S RRNA
RIBOSOMAL PROTEIN S9
RIBOSOMAL PROTEIN
S10)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		3 / 3
TYR C  88
ARG C  38
SER C  35
1.67A7.20
6.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_C_PARC500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
PHE C 379
THR C 372
SER A 964
GLU A 970
ASP A 967
1.68A15.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 8
THR C 372
SER A 964
GLU A 970
ASP A 967
1.23A15.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		3 / 3
SER C 456
LYS A 110
SER A 111
0.87A11.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
TYR B 899
ASN B 896
THR B 894
GLY A1075
GLU A1074
1.59A13.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
GLY C 326
TYR C 352
VAL C 382
TYR C 383
SER C 500
1.66A10.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 11
PHE A 784
SER A 861
THR A 865
TYR C 689
GLY A 867
1.80A15.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		6cs2 ACE2
(Homo
sapiens)		5 / 10
TYR D 183
ASP D 509
ASN D 117
TYR D 199
GLY D 104
1.55A19.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
PHE A 741
SER C 950
SER C 985
TYR C 723
GLY C 953
1.30A15.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5NDV_1_PAR13413_1
(25S RIBOSOMAL RNA
5S RIBOSOMAL RNA)		6g13 NUCLEOPROTEIN
(MERS-CoV)		3 / 3
LYS A 356
GLU A 359
LYS D 263
1.12A11.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6iex BETA-2-MICROGLOBULIN
MHC CLASS I ANTIGEN
(Homo
sapiens;
SARSr-CoV)		5 / 12
TYR A  27
GLU C   2
SER A  67
ASP B  53
ASP A  37
1.69A21.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_C_PARC500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6iex BETA-2-MICROGLOBULIN
MHC CLASS I ANTIGEN
(Homo
sapiens)		5 / 10
SER B  55
THR A  24
TYR A  74
GLU A  63
GLY A  26
1.69A11.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6iex BETA-2-MICROGLOBULIN
MHC CLASS I ANTIGEN
(Homo
sapiens)		5 / 12
SER B  52
LEU A  32
TYR A  27
ASP A  30
GLY A 237
1.60A11.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6iex MHC CLASS I ANTIGEN
(Homo
sapiens)		5 / 12
LEU A  32
THR A  31
ASP A  30
ASP A  29
TYR A 171
1.69A21.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_C_PARC500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6jyt HELICASE
(SARSr-CoV)		5 / 10
SER B 377
PHE B 422
TYR B 398
ASP B 435
TYR B 457
1.71A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5NDV_1_PAR13413_1
(25S RIBOSOMAL RNA
5S RIBOSOMAL RNA)		6jyt HELICASE
(SARSr)		3 / 3
LYS B 139
GLU B 143
LYS B 146
0.75A7.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LF7_A_PARA1817_1
(16S RRNA
RIBOSOMAL PROTEIN S9
RIBOSOMAL PROTEIN
S10)		6kl2 NUCLEOPROTEIN
(MERS-CoV)		3 / 3
TYR B  99
ARG B 138
SER B  42
1.41A22.58
20.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6lzg ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
GLY B 476
TYR A  83
LEU A  97
GLU A  22
VAL A  93
1.55A23.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_2
(AAC(6')-IB)		6m17 ACE2
SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		3 / 3
TRP B 742
GLN A 145
TRP A 135
1.78A14.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		4 / 8
PHE A 473
SER A 483
ASP A 189
TYR A 177
1.35A18.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6m17 ACE2
(Homo
sapiens)		5 / 12
TYR B  83
LEU B  97
GLU B  22
VAL B  93
ASP B  30
1.55A14.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
GLY A 397
TYR A 177
LEU A 181
GLN A 479
SER A 134
1.57A16.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m1d ACE2
(Homo
sapiens)		5 / 10
PHE B 643
PHE B 683
SER B 646
GLU D 668
GLY B 666
1.74A19.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE B 159
SER B  10
GLU B 290
ASP B 295
1.42A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.40A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE D   3
SER D 301
SER B 139
GLU B  14
1.80A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE C 159
SER C  10
GLU C 290
ASP C 295
1.39A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.37A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m71 NSP12
(SARS-CoV-2)		4 / 8
SER A 549
SER A 814
ASP A 761
ASP A 618
1.47A17.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m71 NSP12
NSP7
(SARS-CoV-2)		4 / 8
SER C  10
SER C  15
ASP A 846
TYR A 420
1.73A12.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m71 NSP12
(SARS-CoV-2)		5 / 10
PHE A 812
THR A 604
SER A 754
ASP A 608
GLY A 584
1.62A17.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6m71 NSP12
(SARS-CoV-2)		5 / 12
GLY A 345
TYR A 530
LEU A 527
SER A 561
ASP A 377
1.76A12.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m71 NSP12
(SARS-CoV-2)		5 / 12
PHE A 812
THR A 604
SER A 754
ASP A 608
GLY A 584
1.75A17.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_C_PARC500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6m71 NSP12
(SARS-CoV-2)		5 / 10
PHE A 812
THR A 604
SER A 754
ASP A 608
GLY A 584
1.61A17.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		6m71 NSP12
(SARS-CoV-2)		5 / 10
ASP A 833
TYR A 831
HIS A 872
ASP A 879
GLU A 876
1.79A14.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
SER A 541
LYS A 543
SER A 542
1.74A10.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6nb7 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
PHE A 784
PHE A 779
THR A 863
TYR A 771
GLY A 862
1.66A14.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6nb7 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
PHE A 784
PHE A 779
THR A 863
TYR A 771
GLY A 862
1.68A14.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
(Homo
sapiens)		3 / 3
SER H 141
LYS H 143
SER H 144
1.73A24.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
(Homo
sapiens)		4 / 8
PHE H  29
SER H  53
ASP H 115
ASP H 101
1.41A18.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6nus NSP12
(SARSr-CoV)		5 / 12
LEU A 241
SER A 185
TYR A 237
GLU A 254
GLY A 179
1.64A17.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6nus NSP12
(SARSr-CoV)		5 / 12
GLY A 345
TYR A 530
LEU A 527
SER A 561
ASP A 377
1.62A12.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
PHE C 802
PHE C 797
THR C 881
TYR C 789
GLY C 880
1.69A16.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE C 759
SER B1003
LEU B1001
THR B 998
ASP B 994
1.66A16.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR C 917
ASN C 914
THR C 912
GLY B1093
GLU B1092
1.75A13.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6vw1 ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 10
PHE A 390
PHE A  40
ASP E 406
ASP E 405
GLY A 354
1.59A21.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6vw1 ACE2
(Homo
sapiens)		4 / 8
THR B 294
ASP B 368
ASP B 367
TYR B 279
1.15A21.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6vw1 ACE2
(Homo
sapiens)		5 / 12
TYR B  83
LEU B  97
GLU B  22
VAL B  93
ASP B  30
1.44A15.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6vw1 ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
PHE A 390
PHE A  40
ASP E 406
ASP E 405
GLY A 354
1.55A21.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6vw1 ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
GLY F 476
TYR B  83
LEU B  97
GLU B  22
VAL B  93
1.48A19.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
PHE B 802
PHE B 797
THR B 881
TYR B 789
GLY B 880
1.75A15.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
PHE C 802
PHE C 797
THR C 881
TYR C 789
GLY C 880
1.74A15.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU C 858
THR C 859
SER C 735
ASP B 614
GLY B 593
1.67A15.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 8
SER H   7
THR H   9
GLU H 148
TYR H  90
1.74A16.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE C 377
SER C 366
THR C 385
ASP H 101
1.76A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w41 CR3022 FAB LIGHT
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE C 464
THR C 430
SER C 514
TYR L  92
1.76A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 12
GLY L 212
TYR L 192
LEU L 181
SER L 127
ASP L 122
1.69A20.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6MB7_A_PARA900_0
(AAC(3)-IIIB PROTEIN)		6w4b NSP9
(SARS-CoV-2)		5 / 10
TYR A  67
THR A  68
THR A  20
GLY A  18
ASP A  51
1.72A19.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w4h NSP16
(SARS-CoV-2)		5 / 12
PHE A6868
LEU A6883
THR A6880
TYR A6845
ASP A6904
1.56A18.85
None
None
None
SAM  A7102 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5NDV_1_PAR13413_1
(25S RIBOSOMAL RNA
5S RIBOSOMAL RNA)		6w4h SARS-COV-2 NSP16
(SARS-CoV-2)		3 / 3
LYS A6968
GLU A7001
LYS A6844
0.89A10.29
ACT  A7103 ( 4.0A)
ACT  A7103 ( 4.1A)
ACT  A7103 ( 3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
SER B4325
SER A6872
ASP A6897
ASP A6895
1.59A
None
SAM  A7104 (-4.4A)
SAM  A7104 (-2.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
PHE A6868
LEU A6883
THR A6880
TYR A6845
ASP A6904
1.53A
None
None
None
SAM  A7104 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w75 NSP16
(SARS-CoV-2)		5 / 12
PHE A6868
LEU A6883
THR A6880
TYR A6845
ASP A6904
1.56A19.02
None
None
None
SAM  A7102 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w75 NSP16
(SARS-CoV-2)		5 / 12
PHE C6868
LEU C6883
THR C6880
TYR C6845
ASP C6904
1.57A19.02
None
None
None
SAM  C7105 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 8
SER D4325
SER C6872
ASP C6897
ASP C6895
1.69A16.67
None
SAM  C7105 ( 4.4A)
SAM  C7105 ( 2.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w75 NSP16
(SARS-CoV-2)		4 / 8
SER C6903
SER C6872
GLU C7001
ASP C6928
1.70A19.02
None
SAM  C7105 ( 4.4A)
FMT  C7108 ( 3.9A)
SAM  C7105 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 8
SER B4325
SER A6872
ASP A6897
ASP A6895
1.68A16.67
None
SAM  A7102 ( 4.6A)
SAM  A7102 ( 2.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE C 147
THR C 168
GLU C 161
TYR C 273
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE B 147
THR B 168
GLU B 161
TYR B 273
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
THR C 102
SER C 103
GLU C 143
TYR C 136
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
THR B 102
SER B 103
GLU B 143
TYR B 136
1.61A
None
CL  B 502 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 147
THR A 168
GLU A 161
TYR A 273
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
SER A 103
THR A 115
ASP A 302
TYR C 268
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 11
PHE B 241
THR B 119
TYR B 136
GLU B 263
TYR B 273
1.73A19.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
SER B 103
THR B 115
ASP B 302
TYR A 268
1.40A
 CL  B 502 ( 4.4A)
CL  B 502 ( 4.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE B 304
THR B 115
ASP B 286
TYR B 264
1.49A
None
CL  B 502 ( 4.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
SER C 103
THR C 115
ASP C 302
TYR B 268
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE C 304
THR C 115
ASP C 286
TYR C 264
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
PHE E 315
SER E 310
THR F 296
ASP F 297
TYR F 268
1.65A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE B 314
THR A 334
SER A 318
GLU A 323
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
PHE A 315
SER A 310
THR B 296
ASP B 297
TYR B 268
1.75A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE A 286
THR A 296
ASP A 297
TYR A 268
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
PHE F 315
SER F 310
THR E 296
ASP E 297
TYR E 268
1.76A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
PHE B 315
SER B 310
THR A 296
ASP A 297
TYR A 268
1.74A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE C 314
THR D 334
SER D 318
GLU D 323
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE F 286
THR F 296
ASP F 297
TYR F 268
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 8
PHE D 315
SER D 310
THR C 296
ASP C 297
TYR C 268
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE A 314
THR B 334
SER B 318
GLU B 323
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 10
PHE B 315
SER B 310
THR A 296
ASP A 297
TYR A 268
1.65A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 8
PHE A 315
SER A 310
THR B 296
ASP B 297
TYR B 268
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
PHE D 315
SER D 310
THR C 296
ASP C 297
TYR C 268
1.63A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 10
PHE A 315
SER A 310
THR B 296
ASP B 297
TYR B 268
1.65A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
PHE C 315
SER C 310
THR D 296
ASP D 297
TYR D 268
1.65A12.05
None
None
CL  D 401 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 8
PHE E 315
SER E 310
THR F 296
ASP F 297
TYR F 268
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
PHE F 315
SER F 310
THR E 296
ASP E 297
TYR E 268
1.64A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 10
PHE C 315
SER C 310
THR D 296
ASP D 297
TYR D 268
1.68A12.05
None
None
CL  D 401 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE C 286
THR C 296
ASP C 297
TYR C 268
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 8
PHE F 315
SER F 310
THR E 296
ASP E 297
TYR E 268
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE E 286
THR E 296
ASP E 297
TYR E 268
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 10
PHE E 315
SER E 310
THR F 296
ASP F 297
TYR F 268
1.66A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_F_PARF500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
PHE D 315
SER D 310
THR C 296
ASP C 297
TYR C 268
1.74A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 10
PHE F 315
SER F 310
THR E 296
ASP E 297
TYR E 268
1.66A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 8
PHE C 315
SER C 310
THR D 296
ASP D 297
TYR D 268
1.63A
None
None
CL  D 401 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
PHE B 315
SER B 310
THR A 296
ASP A 297
TYR A 268
1.63A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PHE B 286
THR B 296
ASP B 297
TYR B 268
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_A_PARA500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 10
PHE D 315
SER D 310
THR C 296
ASP C 297
TYR C 268
1.65A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_B_PARB500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 9
PHE A 315
SER A 310
THR B 296
ASP B 297
TYR B 268
1.63A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 8
PHE B 315
SER B 310
THR A 296
ASP A 297
TYR A 268
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
SER D4325
SER C6872
ASP C6897
ASP C6895
1.56A
None
SAH  C7102 (-4.7A)
SAH  C7102 (-2.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
SER B4325
SER A6872
ASP A6897
ASP A6895
1.61A
None
SAH  A7102 ( 4.6A)
SAH  A7102 (-2.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
PHE A6868
LEU A6883
THR A6880
TYR A6845
ASP A6904
1.55A
None
None
None
SAH  A7102 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
PHE C6868
LEU C6883
THR C6880
TYR C6845
ASP C6904
1.58A
None
None
None
SAH  C7102 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 8
SER D4325
SER C6872
ASP C6897
ASP C6895
1.65A
None
SFG  C7103 ( 4.5A)
SFG  C7103 ( 2.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wkq NSP16
(SARS-CoV-2)		4 / 8
SER C6903
SER C6872
GLU C7001
ASP C6928
1.66A
None
SFG  C7103 ( 4.5A)
None
SFG  C7103 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 8
SER B4325
SER A6872
ASP A6897
ASP A6895
1.65A
None
SFG  A7103 ( 4.5A)
SFG  A7103 ( 2.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wkq NSP16
(SARS-CoV-2)		5 / 12
PHE C6868
LEU C6883
THR C6880
TYR C6845
ASP C6904
1.58A
None
None
None
SFG  C7103 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wkq NSP16
(SARS-CoV-2)		5 / 12
PHE A6868
LEU A6883
THR A6880
TYR A6845
ASP A6904
1.56A
None
None
None
SFG  A7103 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
PHE A6868
LEU A6883
THR A6880
TYR A6845
ASP A6904
1.55A
None
None
None
SAH  A7101 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
SER B4325
SER A6872
ASP A6897
ASP A6895
1.60A
None
SO4  A7109 (-4.5A)
SAH  A7101 (-2.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		6wqd NSP7
(SARS-CoV-2)		3 / 3
SER C   1
LYS C   2
SER C   4
0.87A17.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		6wqd NSP7
(SARS-CoV-2)		3 / 3
SER C   1
LYS C  -1
SER C   4
1.46A17.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 8
PHE A 147
THR A 168
GLU A 161
TYR A 273
1.59A
None
None
None
GOL  A 508 (-4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 8
PHE A 304
THR A 115
ASP A 286
TYR A 264
1.37A
None
None
None
GOL  A 508 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		6xip NSP7
(SARS-CoV-2)		3 / 3
SER A   1
LYS A   2
SER A   4
1.19A17.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.41A15.33
None
None
None
DMS  A 403 ( 4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 8
PHE D  92
THR C   9
ASP A   5
ASP C   5
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
SER C   1
LYS C   2
SER C   4
0.59A17.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 8
SER C  15
THR D  84
GLU D  77
ASP D  78
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		3 / 3
SER C  25
LYS C  27
SER C  26
1.36A17.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 8
PHE B  92
THR A   9
ASP C   5
ASP A   5
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		5 / 12
GLY A  29
TYR A  83
LEU A  73
TYR A  72
SER A  38
1.49A21.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE E 377
SER E 366
THR E 385
ASP H 107
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE A 377
SER A 366
THR A 385
ASP B 107
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
THR B 104
TYR C  31
GLU C  61
TYR B  32
GLY B  99
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6yla LIGHT CHAIN
(Homo
sapiens)		5 / 12
GLY C 218
TYR C 198
LEU C 187
SER C 133
ASP C 128
1.65A21.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
PHE A 515
THR B 104
TYR C  38
TYR B  32
GLY B 101
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
THR H 104
TYR L  31
GLU L  61
TYR H  32
GLY H  99
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6yla LIGHT CHAIN
(Homo
sapiens)		5 / 12
GLY L 218
TYR L 198
LEU L 187
SER L 133
ASP L 128
1.59A21.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE E 464
THR E 430
SER E 514
TYR L  98
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE A 464
THR A 430
SER A 514
TYR C  98
1.73A
None
None
None
DMS  C 303 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ym0 LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE E 464
THR E 430
SER E 514
TYR L  98
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6ym0 LIGHT CHAIN
(Homo
sapiens)		5 / 12
GLY L 218
TYR L 198
LEU L 187
SER L 133
ASP L 128
1.62A21.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ym0 HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE E 377
SER E 366
THR E 385
ASP H 107
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6yor IGG L CHAIN
(Homo
sapiens)		5 / 12
GLY L 218
TYR L 198
LEU L 187
SER L 133
ASP L 128
1.59A21.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE E 377
SER E 366
THR E 385
ASP H 107
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE E 464
THR E 430
SER E 514
TYR L  98
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE A 377
SER A 366
THR A 385
ASP B 107
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		6yor IGG L CHAIN
(Homo
sapiens)		5 / 12
GLY C 218
TYR C 198
LEU C 187
SER C 133
ASP C 128
1.59A21.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PHE A 464
THR A 430
SER A 514
TYR C  98
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		5 / 12
THR H 104
TYR L  31
GLU L  61
TYR H  32
GLY H  99
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		5 / 12
THR B 104
TYR C  31
GLU C  61
TYR B  32
GLY B  99
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.35A
None
None
None
CL  A 406 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER E 167
SER C   7
ASP B  67
TYR B  42
1.56A
None
None
EDO  C 203 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER E 167
SER C   7
ASP B  67
TYR B  42
1.63A
None
None
EDO  B 203 ( 3.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
SER A  10
GLU A 290
ASP A 295
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		7btf NSP12
(SARS-CoV-2)		5 / 12
GLY A 214
TYR A 217
VAL A  71
TYR A  69
ASP A  67
1.34A12.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A  45
THR A 206
ASP A 221
TYR A 217
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
SER A 549
SER A 814
ASP A 761
ASP A 760
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7btf NSP12
NSP7
(SARS-CoV-2)		5 / 12
PHE A 843
PHE A 415
LEU C  14
GLU C  47
ASP C  38
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A  70
THR A 120
SER A  68
GLU A 144
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
SER A 549
SER A 814
ASP A 761
ASP A 618
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		7btf NSP7
(SARS-CoV-2)		3 / 3
SER C   1
LYS C   2
SER C   4
0.69A18.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		7btf NSP12
(SARS-CoV-2)		5 / 12
GLY A 345
TYR A 530
LEU A 527
SER A 561
ASP A 377
1.61A12.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
THR A 540
SER A 561
ASP A 684
TYR A 453
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A  45
THR A 206
SER A 236
ASP A 221
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
SER A 784
GLU A 167
ASP A 161
ASP A 164
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 506
THR A 540
SER A 561
ASP A 684
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
GLY A 345
TYR A 530
LEU A 527
SER A 561
ASP A 377
1.69A12.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_D_PARD500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		7bv2 NSP12
NSP7
(SARS-CoV-2)		4 / 8
PHE A 843
SER A 835
SER C   4
GLU C  47
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AZ3_1_PAR11803_1
(RRNA ALPHA
RIBOSOMAL PROTEIN
EL18)		7bv2 NSP7
(SARS-CoV-2)		3 / 3
SER C  25
LYS C  27
SER C  26
1.52A17.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VQY_A_PARA1201_1
(AAC(6')-IB)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
GLY A 345
TYR A 530
LEU A 527
SER A 561
ASP A 377
1.79A12.43
None